Survival rates

The chance of surviving non-Hodgkin lymphoma is different for every person. Factors include your type of non-Hodgkin lymphoma, your overall health, the stage of your cancer and which treatments you are getting. To understand non-Hodgkin lymphoma survival rates, experts study many people with non-Hodgkin lymphoma to see how many are living five years after their diagnosis.

For stage 1 non-Hodgkin lymphoma, the chance of surviving at least five years is about 88%. As the cancer spreads, the chances get lower. For stage 4 non-Hodgkin lymphoma, the chance of surviving at least five years is about 64%.

Survival rates vary depending on the type of non-Hodgkin lymphoma. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. It is an aggressive type, so the survival rates are often lower. At stage 1, the chance of surviving at least five years is 80%. For stage 4 diffuse large B-cell lymphoma, the chance of surviving at least five years is about 55%.

Follicular lymphoma is another common type of non-Hodgkin lymphoma. It is an indolent type, meaning it grows slowly. The survival rates are often higher. For stage 1 follicular lymphoma, the chance of surviving at least five years is about 97%. For stage 4 follicular lymphoma, the chance of surviving at least five years is about 83%.

Keep in mind that survival statistics take five years to collect. The most recent survival rates include people who had non-Hodgkin lymphoma treatment more than five years ago. These people may not have had access to the latest treatments. Over the last few decades, non-Hodgkin lymphoma death rates have been falling and survival rates have been increasing.

Nov. 07, 2025

Living with linfoma no Hodgkin?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

atir
Polycythemia Vera: Just been diagnosed

440 Replies Sat, Nov 15, 2025

Tracy
Has anyone been diagnosed with POEMS syndrome?

18 Replies Sat, Nov 15, 2025

Colleen Young, Connect Director
Have you ever had hiccups with or after chemotherapy?

121 Replies Fri, Nov 14, 2025

See more discussions
  1. B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Aug. 30, 2024.
  2. T-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483. Accessed Aug. 30, 2024.
  3. Non-Hodgkin lymphoma (NHL). Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma. Accessed Sept. 16, 2024.
  4. DeVita VT Jr, et al., eds. Non-Hodgkin lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Aug. 28, 2024.
  5. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Aug. 29, 2024.
  6. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Sept. 17, 2024.
  7. Member institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Sept. 17, 2024.
  8. Bock AM, et al. Bispecific antibodies for non-Hodgkin lymphoma treatment. Current Treatment Options in Oncology. 2022; doi:10.1007/s11864-021-00925-1.
  9. Tun AM, et al. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treatment Reviews. 2020; doi:10.1016/j.ctrv.2020.102042.
  10. Nowakowski GS, et al. Integrating precision medicine through evaluation of cell of origin treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal. 2019; doi:10.1038/s41408-019-0208-6.
  11. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083.
  12. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025.
  13. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Oct. 1, 2025.
  14. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Oct. 1, 2025.
  15. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Oct. 1, 2025.
  16. Cancer stat facts: NHL — Diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Oct. 1, 2025.
  17. Cancer stat facts: NHL — Follicular lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Oct. 1, 2025.